By Brinter Ltd.
To get in touch with Brinter Ltd., simply fill out the form below.
Subscribe to Supplier
Innovative Brinter® 3D bioprinters constructed using advanced HP Multi Jet Fusion 3D printing technology
Turku, Finland: – Trailblazing Finnish 3D bioprinting specialist Brinter® has adopted leading-edge HP Multi Jet Fusion 3D printing technology to help it build its innovative bioprinting solutions faster and more sustainably.
The use of Multi Jet Fusion (MJF) construction is in line with the Brinter® vision of expanding life sciences adoption of multi-material bioprinting by custom building bioprinters to specific customer needs at the lowest possible cost and with minimal waste.
Making bioprinting more accessible
The company’s modular bioprinter platforms, such as the Brinter® One, can be used in a variety of applications, such as a versatile tool for basic research in tissue engineering and regenerative medicine. The use of 3D bioprinting solutions also offers a cost-effective approach to shorten and enhance drug discovery.
“Our objective was to use new print tools to create innovative business solutions that put bioprinting within reach of every pharmaceutical company, hospital, university, and research center,” commented Brinter® CEO and co-founder, Tomi Kalpio.
Accelerated time to market
If traditional manufacturing methods were used, new versions of Brinter® medical components would require weeks or months to be manufactured and tested. At the same time, relying on geographically distributed suppliers represented a risk that has been highlighted by the supply chain disruption that accompanied the COVID-19 pandemic and geopolitical tensions.
For parts manufacturing, Brinter® has increasingly partnered with fellow Finnish company 3DTech Oy, who relies on HP Jet Fusion 4200 3D Printers. The use of MJF technology has allowed the partners to speed up R&D and NPI processes, with components now able to be tested within days, allowing new Brinter® concepts to be translated more quickly into final products, and innovative technology and protocols brought to market much faster.
High MJF content
The Brinter® One modular bioprinting platform includes some 80 custom-made medical equipment 3D components, of which more than 60 are 3D-printed using HP Multi Jet Fusion (MJF) technology.
Tangible advantages include:
- All specifically shaped components, such as integrated 3D-printed sockets for individual electrical and pneumatics components, tubings, and cover plates, are printed to individual application with no need to keep physical parts in stock.
- All end-user medical equipment parts can be designed and formed to optimize them for specific application needs, rather than conforming to the manufacturing method.
- MJF technology uses HP 3D High Reusability (HR) PA 12 material for minimal waste and high recyclability, meeting Brinter® sustainability goals.
- Shorter and more secure supply chains.
Additive manufacturing synergies
“The combination of HP’s 3D medical equipment printing, 3DTech’s services, and Brinter® products is a match made in heaven, as all three companies share a passion for additive manufacturing,” says Tomi Kalpio.
The Brinter® platform is unique in the medical market due to its high modularity and authentic multi-material printing capabilities—all features made possible because of HP’s 3D printing technology for medical equipment.
From rapid prototyping to rapid production
“It is amazing to see how the 3D Printing industry has changed over the past 20 years since my introduction to 3D technology. The technology was then called ‘rapid prototyping’, and for a reason,” Mr. Kalpio reflected.
“When you think about HP’s mass production systems or our multi-material printing systems, today’s technology is radically different compared to what we had back then. Now we can produce the parts with the same production method as the prototypes, fast and in series with the ability to personalize and develop parts further without requiring changes in the manufacturing process,” the Brinter® CEO explained.
Kalpio points out that this is part of a virtuous circle in which new applications made possible by advanced 3D print manufacturing will facilitate future clinical solutions that expand bioprinting for the treatment of diseases.
HP’s 3D printing for medical equipment enabled the creation of innovative business solutions using new print tools and options that in turn expand the Brinter® portfolio of material and printing protocols, reinforcing the Finnish company’s credentials as a global technology forerunner in the bio- and medical industries, and in the areas of material research and development.
Founded in 2020 via partial demerger in Turku, Finland, Brinter® is the manufacturer of a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company works with science and bioengineering organizations to integrate 3D bioprinting into their research, manufacturing, and treatment methods. The goal is to break through current technological limitations and improve people’s quality of life.
Brinter® has bootstrapped its growth since 2019, when it launched its first product, and is currently active in more than ten countries, including the USA, Germany, India, and the UK.
Customers of the company now include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki, whose directors are enthusiastic about the technology’s potential.
For more information, visit www.brinter.com.